The dual impact of coxsackie and adenovirus receptor expression on human prostate Cancer gene therapy

• Published in: Cancer research (Chicago, Ill.) Vol. 60; no. 18; pp. 5031 - 5036
• Main Authors: OKEGAWA, Takatsugu, LI, Yingming, PONG, Rey-Chen, BERGELSON, Jeffrey M, JIAN ZHOU, HSIEH, Jer-Tsong
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15-09-2000
• Subjects: Adenoviridae - genetics; Adenovirus; Animals; Antineoplastic agents; Biological and medical sciences; Cell Division - physiology; Chemotherapy; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Genetic Therapy; Genetic Vectors; human coxsackievirus; Humans; Male; Medical sciences; Mice; Mice, Nude; Neoplasm Transplantation; Pharmacology. Drug treatments; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Receptors, Virus - biosynthesis; Receptors, Virus - genetics; Receptors, Virus - physiology; Transfection; Tumor Cells, Cultured; Antineoplastic agent; Cell proliferation; Potentiation; Coxsackievirus; Adenoviridae; Prostate disease; Picornaviridae; Gene overexpression; Enterovirus; Transfection; Established cell line; Mechanism of action; Male genital diseases; Biological receptor; Human; Urinary system disease; Tumorigenicity; Malignant tumor; Gene expression; In vitro; Virus; Infection; Sensitivity resistance; Gene therapy; Prostate
• ISSN: 0008-5472; 1538-7445

In a recent paper, we reported a significant difference in coxsackie and adenovirus receptor (CAR) from several human bladder cancer cell lines that correlated with their sensitivities to adenoviral infection (Y. Li, R-C. Pong, J. M. Bergelson, M. C. Hall, A. I. Sagalowsky, C-P. Tseng, Z. Wang, and J. T. Hsieh, Cancer Res., 59: 325-330, 1999). In human prostate cancer, CAR protein is down-regulated in the highly tumorigenic PC3 cell line, which suggests that, in addition to its function as a viral receptor, CAR may have a pathophysiological role in prostate cancer progression. In this paper, we document that CAR does not merely enhance the viral sensitivity of prostate cancer cells but also acts as a tumor inhibitor for androgen-independent prostate cancer cells. Our data indicate that CAR is a potential therapeutic agent for increasing the efficacy of prostate cancer therapy.